Astonea Labs
Close ·
Key Fundamentals
SMEPharmaceuticals & BiotechnologyHealthcarePrice-based figures at the close · TTM
- ROCE
- 10.50%
- Debt to Equity
- 0.74
- EPS (TTM)
- —
- Book Value
- ₹54.35
- Market Cap
- —
- P/E (TTM)
- —
- P/B
- 6.16
- ROE
- 12.00%
- Dividend Yield
- 0.00%
- EBITDA
- ₹13.90 Cr
- 52W High
- ₹369.00
- 52W Low
- ₹118.00
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 81/100
Category scores
- Quality
- 37
- Poor
- Returns, margins, earnings quality 22% weight
- Valuation
- 25
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 92
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 29
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 99
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 49
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
No strengths listed
Weaknesses
3- Stock is trading at 5.96 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 41.3 days to 74.2 days
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 1 | 7 | 11 |
| Oscillators | Neutral | 1 | 7 | 1 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Neutral
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 58.48
- Neutral
- MACD (12,26,9)
- 10.89
- Bearish
- SMA (50)
- 298.63
- Bullish
- SMA (200)
- 206.12
- Bullish
As of
Growth Rate
From the financial statements below. 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 3Y | +30.24% |
|---|---|
| 1Y | +51.02% |
Net profit
| 3Y | +71.00% |
|---|---|
| 1Y | 0.00% |
Operating cash flow
| 3Y | Outflow widened by ₹13 Cr |
|---|---|
| 1Y | Turned negative |
Operating margin· change in pp
| 3Y | −0.99 pp |
|---|---|
| 1Y | −5.85 pp |
Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2022 | ₹30.00 Cr |
|---|---|
| Mar 2023 | ₹67.00 Cr |
| Mar 2024 | ₹80.00 Cr |
| Mar 2025 | ₹98.00 Cr |
| Mar 2026 | ₹148 Cr |
Net profit by year
| Mar 2022 | ₹0.00 Cr |
|---|---|
| Mar 2023 | ₹1.00 Cr |
| Mar 2024 | ₹4.00 Cr |
| Mar 2025 | ₹5.00 Cr |
| Mar 2026 | ₹5.00 Cr |
Half-yearly Results
₹ Cr| Particulars | Sep 2024 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 47 | 66 | 81 |
| Expenses | 41 | 61 | 73 |
| Operating Profit | 7 | 5 | 8 |
| OPM % | 14% | 8% | 10% |
| Other Income | 0 | 0 | 0 |
| Interest | 2 | 2 | 2 |
| Depreciation | 2 | 2 | 3 |
| PBT | 3 | 2 | 4 |
| Tax % | 24% | 20% | 20% |
| Net Profit | 2 | 1 | 3 |
| EPS (₹) | 2.76 | 1.35 | 2.95 |
Profit & Loss
₹ Cr| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 30 | 67 | 80 | 98 | 148 |
| Expenses | 24 | 60 | 68 | 82 | 134 |
| Operating Profit | 6 | 7 | 12 | 15 | 14 |
| OPM % | 19% | 11% | 15% | 16% | 9% |
| Other Income | 0 | 0 | 0 | 0 | 1 |
| Interest | 2 | 2 | 3 | 4 | 3 |
| Depreciation | 4 | 4 | 4 | 5 | 5 |
| PBT | 1 | 1 | 5 | 7 | 6 |
| Tax % | 57% | 39% | 24% | 24% | 20% |
| Net Profit | 0 | 1 | 4 | 5 | 5 |
| EPS (₹) | 0.33 | 0.88 | 5.36 | 6.93 | 4.3 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
₹ Cr| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 8 | 8 | 11 |
| Reserves | 3 | 4 | 4 | 11 | 47 |
| Borrowings | 30 | 36 | 42 | 53 | 43 |
| Other Liabilities | 16 | 20 | 26 | 32 | 46 |
| Total Liabilities | 53 | 64 | 81 | 103 | 146 |
| Fixed Assets | 21 | 21 | 22 | 26 | 31 |
| CWIP | 0 | 0 | 2 | 4 | 8 |
| Investments | 0 | 0 | 0 | 0 | 6 |
| Other Assets | 32 | 44 | 57 | 73 | 101 |
| Total Assets | 53 | 64 | 81 | 103 | 146 |
Cash Flow
₹ Cr| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating | −5 | −1 | 8 | 9 | −14 |
| Investing | −3 | −3 | −8 | −11 | −20 |
| Financing | 8 | 4 | 0 | 2 | 34 |
| Net Cash Flow | 0 | 0 | −1 | 0 | 0 |
| Free Cash Flow | −8 | −4 | 0 | −2 | −28 |
| CFO/EBITDA | −75 | −9 | 71 | 70 | −88 |
Ratios
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debtor Days | 235 | 104 | 116 | 142 | 129 |
| Inventory Days | 136 | 121 | 161 | 161 | 125 |
| Days Payable | 273 | 128 | 149 | 144 | 150 |
| Cash Conversion Cycle | 98 | 97 | 128 | 159 | 103 |
| Working Capital Days | 98 | 33 | 28 | 22 | 74 |
| ROCE % | — | 8% | 17% | 17% | 11% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Astonea Labs insights
50 extracted metrics across FY22–FY26.
Documents
- General announcements 8 Oct 2026
- General announcements 8 Oct 2026
Frequently Asked Questions about Astonea Labs
What does Astonea Labs Ltd do?
Where is Astonea Labs Ltd (ASTONEALAB) listed?
Which sector does Astonea Labs Ltd belong to?
What is the 52-week high and low of Astonea Labs Ltd?
What is the Return on Equity (ROE) of Astonea Labs Ltd?
Company Information
Incorporated in 2017, Astonea Labs Ltd. is engaged in contract manufacturing of pharmaceutical and cosmetic products for companies
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/544409.md for Astonea Labs Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.